Role of Kynurenine Pathway and Its Metabolites in Depressive Disorders, Major Depressive Disorder is Suspected to Have the Greatest Burden by 2030,Kynurenine Pathway is Major Route Through Which the Essential Amino Acid Tryptophan is Metabolised and Activated in Time of Stress and Immune Activation.
- Sponsor
- Sohag University
- Study ID
- NCT07771517
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
- Major Depressive Disorder (MDD)
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 18 Years
- Healthy Volunteers
- Accepted
Study Details
This is a case control study including simple random cases of 90 persons, 45 of them have depressive disorders and the other 45 are healthy individuals,age group between 18-60 years old, cases will be recruited from outpatient psychiatric clinic in sohag university hospital, all cases will be exposed to psychological assessment and also laboratory assessment of kynurenine metabolites by using biokits
Key Dates
- First listed
- Aug 18, 2026
- Start date
- Mar 14, 2027
- Status verified
- Aug 2026
- Primary completion
- Aug 20, 2028
- Completion
- May 20, 2029
Study Design
- Enrollment
- 90 participants (estimated)
Primary Outcome Measure
Psychological assessment of patients with depressive disorders [ Time Frame: From the enrollment of all cases till three months later ]
Related Studies
- Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning DeficitsRecruiting · Portland VA Medical Center · Portland, Oregon
- Pilot Study: Establishing Glutamatergic Changes in Rapid Antidepressant Effects of KetamineEARLY_PHASE1 · Recruiting · University of Pennsylvania · Philadelphia, Pennsylvania
- A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive DisorderPHASE3 · Recruiting · Cybin IRL Limited · Birmingham, Alabama
- Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive DisorderPHASE3 · Recruiting · Vanda Pharmaceuticals · Phoenix, Arizona